Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients
ConclusionsAnti-CGRP mAbs are safe and effective treatments in migraine patients over 65 years old in real-life clinical practice.Graphical Abstract
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Diabetes | Endocrinology | Headache | Heart | Hypertension | Migraine | Neurology | Pain | Spain Health | Study | Women